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Objective: There is strong evidence of a link between the use of systemic bisphosphonates (BPs) and osteonecrosis of the jaw, especially in cancer patients. Among risk factors 
for BRONJ, tooth extraction and immune suppressive drugs seem to have significant role 
on bone healing. Therefore, the importance of these parameters in development of BRONJ 
was reviewed in this retrospective study in two maxillofacial surgery units. Material and 
Methods: From 2007 to 2012, 46 patients on bisphosphonate who had developed oral bony 
lesions participated in this study. The pharmacological exposure, comorbidities, maxillofacial 
findings, types of treatment and outcome data were collected from clinical and radiological 
records. Results: The most frequently used BP was alendronate (67%). Tooth extraction 
was reported in 61% of patients with BRONJ. Systemic corticosteroids were prescribed in 
35 cases (76%) as an adjuvant for BP. Patients on corticosteroids had a lower probability of 
bony lesion healing (p<0.05) than patients without corticosteroids. Of the 46 patients who 
underwent conservative treatments, only ten were completely healed (21%). Conclusions: 
Beside tooth extraction, corticosteroids were shown to be an implant risk factor for low 
rate of bone healing and hence the development of BRONJ. The outcome of conservative 
treatment was uncertain and this emphasizes the importance of prevention.
Keywords: Bisphosphonates. Jaw. Bisphosphonate-associated osteonecrosis of the jaw. 
Oral health. Osteoporosis.
INTRODUCTION
Bisphosphonates are antiresorptive drugs 
that act specifically on osteoclasts, thereby 
maintaining bone density and strength23. These 
compounds are used in many clinical settings, 
including prevention and treatment of primary 
and secondary osteoporosis, Paget’s disease of 
the bone, hypercalcaemia, multiple myeloma and 
osteolysis associated with bone metastases of 
malignant tumors10. Specially among patients with 
cancer, intravenous bisphosphonate therapy has 
been linked to osteonecrosis of the jaw5,12,18. This 
condition is defined as a non-healing wound with 
exposed bone, persisting for more than 8 weeks 
in a patient receiving bisphosphonates and with 
no history of local radiation therapy19. For patients 
on bisphosphonates, surgical procedures exposing 
the jaw bone to the oral cavity will increase the 
risk of BRONJ5,12,18. The calculated frequency of 
bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) after tooth extraction in high risk patients 
ranges from 7% to 9%19. However, many of these 
cases occur spontaneously (without any apparent 
treatment, trauma, or concurrent disease), and 
most of these have been reported with the use of 
bisphosphonates for a duration of 1.5 to 3 years8.
The pathophysiological basis of BRONJ is 
controversial. Previously, this condition was defined 
as a complication of head and neck radiotherapy6. 
Hence the name osteonecrosis is normally used 
for sterile bone death, typically due to impaired 
blood supply. At the time, it was speculated that 
bisphosphonates could cause necrotic bony lesions 
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due to their effects on blood vessels of the bone, 
possibly by inhibition of the vascular endothelial 
growth factor (VEGF)7,25. More recently, it has been 
suggested that BRONJ does not begin as a form of 
classical osteonecrosis, but in fact it is osteomyelitis 
from the beginning4,11. Microbial contamination such 
as actinomyces seems to play an important role in 
maintaining osteomyelitic wounds21,26.
Since jaw bone containing bisphosphonates 
will be resorbed slowly, it is conceivable that 
bacterially contaminated bone cannot be removed 
fast enough to prevent the development of chronic 
osteomyelitis. This hypothesis is supported by 
the observation that similar lesions appear after 
treatment with an anti-RANKL antibody that reduces 
osteoclast recruitment29. Recently, it was shown 
in a rat model that the immediate mucoperiosteal 
coverage of extraction sockets prevents the 
development of BRONJ1.
Regarding clinical findings, four stages of 
bisphosphonate-induced osteonecrosis of the jaw 
can be identified. Early stages are characterized by 
exposed necrotic bone, with or without symptoms; 
whereas, in the later stages, the presence of 
pathologic fractures, extraoral fistulae and exposed 
necrotic bone extending beyond the region of the 
alveolar bone may be observed3.
The prevalence of BRONJ continues to increase 
worldwide owing to greater awareness of bone 
health20. Therefore, a clearer understanding of 
the pathogenesis and management strategies for 
BRONJ is necessary. The concurrent administration 
of bisphosphonate and corticosteroids, as in many 
patients being treated for multiple myeloma, 
can increase the risk of BRONJ. The importance 
of corticosteroids in the development of BRONJ 
in animal models has been discussed in several 
studies17,27. The main hypothesis of the present 
study was that patients receiving both BPs and 
corticosteroids had a higher risk of developing 
BRONJ. In addition, the success rate and outcome 
of conservative approach was also reviewed.
MATERIAL AND METHODS
Identification of study population
Departments of oral and maxillofacial surgery 
in both Bergen (Norway) and Linköping (Sweden) 
provide health care to approximately half a million 
patients. In these regions, (approximately) 15% of 
the populations are treated with bisphosphonate 
per year because of various reasons. We used 
maxillofacial health databases to identify all 
patients diagnosed with bisphosphonate-related 
bony exposure of the jaw between 2007 and 
2012. Because of the lack of a specific diagnosis 
code for bisphosphonate-related osteonecrosis of 
the jaw prior to 2012, we selected cases from the 
databases that were diagnosed by the following 
criteria: patient a, on bisphosphonate; b, with 
bony exposure (more than 8 weeks); c, with 
osteomyelitis diagnosis. This was followed by 
review of the medical and radiological records to 
confirm the diagnosis of BRONJ in the identified 
cases. Thus, 46 cases of BRONJ were found. 
Orthopanoramic photo and CT-scan showed 
radiolucency in connection with bony lesions in 
all patients. No other abnormality was found. All 
patients in this study had received conservative 
treatment, consisting of local wound care, oral 
antibiotics and minor surgical debridement. BRONJ 
was diagnosed according to the Task Force on 
bisphosphonate-related osteonecrosis of the jaw, 
as defined by the American Association of Oral and 
Maxillofacial Surgeons (AAOMS)3. These include: 
a) exposed bone in the maxillofacial region for 
a period of eight weeks or more, b) current or 
previous treatment with bisphosphonates, and c) 
no prior history of radiation therapy of the jaw. The 
staging of the disease was made according to the 
recommendations of the AAOMS 2014, as outlined 
below22.
Stage 0 - no clinical evidence of necrotic bone 
but nonspecific clinical findings, radiographic 
changes, and symptoms;
Stage 1 - exposed and necrotic bone or fistulas 
that probe to bone in patients who are asymptomatic 
and have no evidence of infection;
Stage 2 - exposed and necrotic bone or fistulas 
that probe to bone associated with infection as 
evidenced by pain and erythema in the region of 
exposed bone with or without purulent drainage;
Stage 3 - exposed and necrotic bone or a fistula 
that probes to bone in patients with pain, infection, 
and ≥1 of the following: exposed and necrotic bone 
extending beyond the region of alveolar bone (i.e., 
inferior border and ramus in mandible, maxillary 
sinus, and zygoma in maxilla) resulting in pathologic 
fracture, extraoral fistula, oral antral or oral nasal 
communication, or osteolysis extending to inferior 
border of the mandible or sinus floor.
Exclusion criteria
Patients with primary or metastatic tumors 
or a history of trauma in the maxillofacial region 
were excluded, as these conditions often induce 
inflammation of the jaw. In addition, all patients 
with a history of radiation therapy were excluded 
from analysis. After the initial review, 48 cases of 
BRONJ were identified (stage 0-III). Two patients 
with stage 0 (diagnosed by radiological findings 
with no history of bone exposure) were excluded 
from the study.
Confounding factors
Data on age, gender, pharmacological exposure 
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(type of bisphosphonate and duration), co-
administration of corticosteroids, maxillofacial 
findings, types of treatment and outcomes were 
collected from the available clinical and radiological 
records. The treatment outcomes were classified 
into two categories: (1) complete healing with 
a covering of normal mucosa or (2) mucosal 
ulceration. All patients with ulceration had exposed 
bone.
Statistics
A descriptive statistical analysis was conducted 
and the results expressed as percentages or mean 
values. The main hypothesis was that patients 
receiving BPs and corticosteroids had a higher risk 
of developing BRONJ. This was examined through 
statistical testing (Fisher’s exact test), and p<0.05 
was considered significant.
RESULTS
Incidence and bisphosphonate
Data was collected from 38 females and 8 
males aged between 57 and 99 years. None of 
the patients were confirmed as having developed 
ONJ due to trauma in the maxillofacial region. 
For all bisphosphonate users, the incidence of 
BRONJ per 100,000 person-years was 0.1 cases. 
The majority of the patients were on alendronate 
(n=31), pamidronate (n=3), ibandronate (n=2) 
or zoledronate (n=9). One patient received 
pamidronate and ibandronate (n=1). Patients in 
Bergen were more likely to receive zoledronate and 
alendronate, while patients in Linköping received 
alendronate and pamidronate. The main reason 
for receiving BP treatment was osteoporosis for 
females and multiple myeloma for males. A total 
of 13 patients (28%) were on IV bisphosphonates. 
The overall onset of BRONJ was earlier in the IV BP 
group (median, 2.5 years) compared to the oral BP 
group (median, 6 years). At the end of the study 
period, only 21% of lesions had healed.
Mucosal trauma ulceration vs. spontaneous 
ulceration
This condition was observed more frequently in 
the mandible (n=37) than in the maxilla (n=8). One 
patient had BRONJ in both the upper and lower jaw. 
Exposed alveolar bone occurs spontaneously (13%) 
or becomes evident following tooth extraction 
(61%) or dental implant (9%). The presence of 
a removable oral prosthesis (full or partial) was 
recorded in 8 patients (17%).
Corticosteroids
Most patients with BRONJ presented in stage II 
(n=35) or stage I (n=8). Of the overall 46 patients 
with BRONJ, 38 did not heal during the observation 
period, including 16 who died from the disease. 
The systemic corticosteroid prednisolone was being 
prescribed (10 to 20 mg per day) in 35 cases (76%). 
Of these, 30 patients (86%) had non-healing bony 
lesions and the majority of them belonged to 
stage II. Patients on corticosteroids had a lower 
probability of healing (p<0.05) than patients who 
were not on corticosteroids.
DISCUSSION
Osteonecrosis of the jaw remains a major 
concern for many patients using bisphosphonates. 
While there have been important advances in the 
diagnosis of BRONJ, the etiology and epidemiology 
of the disease are still poorly understood. Patients 
from two maxillofacial university clinics participated 
in this epidemiological study. Both departments 
have similar treatment strategies and provide care 
to almost one million patients in total.
Patients at high risk of developing BRONJ are 
those with malignant disease receiving high doses 
of intravenous bisphosphonate therapy and/or with 
a history of chemotherapy or concomitant use of 
systemic corticosteroids24. Chronic glucocorticoid 
therapy has adverse effects on bone metabolism, 
including impaired osteoblastic differentiation 
and function. Furthermore, the additional 
immunosuppressive and antiangiogenic effects of 
glucocorticoids can play an important role in the 
development of BRONJ20,22. In the current study, 
the systemic corticosteroid prednisolone was being 
prescribed for 35 patients (76%) and, of these, 30 
patients (86%) had exposed bone at the end of 
the study period. However, this does not mean that 
a patient who has exposed bone suffers from the 
disease. In fact, many patients with BRONJ have no 
symptoms. Another risk factor for the development 
of ONJ was tooth extraction. In the current study, 
a history of tooth extraction was recorded in 28 
patients with ONJ (60%), which is in line with 
previous studies5,14,18.
The incidence of ONJ is estimated to be 1–12% 
in cancer patients receiving high-dose intravenous 
bisphosphonates5,18. The frequency of ONJ in bone 
malignancy cases, especially in those treated with 
intravenous bisphosphonates, was found to be 
1 in 10019. If tooth extractions were performed, 
the calculated frequency of ONJ increased to 1 
in 1019. In a retrospective study, Wang, et al.30 
(2007) found that the incidence of ONJ associated 
with intravenous bisphosphonates was at least 
3.8 per 100 patients with multiple myeloma, 2.5 
per 100 patients with breast cancer, and 2.9 per 
100 patients with prostate cancer. In osteoporosis 
patients, ONJ is rare and the incidence may not 
be greater than the natural background incidence 
of the condition. Epidemiological studies have 
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indicated an estimated incidence of less than 
one case per 100,000 person-years of exposure 
to oral amino bisphosphonates5,18. Recently, in 
an epidemiological study of four Scandinavian 
countries (Denmark, Sweden, Finland and Norway) 
the incidence of ONJ among BP-treated patients was 
estimated to be between 0.7% and 1.3%15. Almost 
two-thirds of the patients with ONJ were IV-users.
In the current study, the incidence of ONJ in 
patients on bisphosphonate was 0.1 cases per 
100,000 person-years. Twenty-eight patients with 
BRONJ had a history of tooth extraction and 80% 
of the patients had a non-healing bony lesion at 
the end of the study period. Similar findings have 
been reported by others14,18.
Various hypotheses have been proposed for 
the pathophysiology of BRONJ, including bacterial 
contamination, bone remodelling suppression 
and angiogenesis suppression. In a prospective 
study by Stopeck, et al.28 (2010), 4,000 patients 
with metastatic bone disease were treated with 
zoledronate or denosumab, a rank ligand antibody 
that potently inhibits osteoclast differentiation and 
function. Osteonecrosis of the jaw was observed 
in both arms of the study (2% in patients treated 
with denosumab and 1.4% in patients treated with 
zoledronic acid). Thus, it appears that reduced 
resorptive activity is a key factor behind the reduced 
ability of these lesions to heal.
I n  a d d i t i o n  t o  t h e s e  h y p o t h e t i c a l 
mechanisms, another recent hypothesis stated 
that bisphosphonates accumulate in bone in 
concentrations sufficient to be directly toxic to the 
oral epithelium. This would result in diminished 
soft-tissue healing, leading to secondary infection 
of the underlying bone. However, the view that 
BRONJ starts with soft-tissue damage has prevailed. 
Recently, in a rat model of ONJ following tooth 
extraction, a high dose of alendronate (200 μg/kg) 
did not cause ONJ-like lesions2. When calculated as 
dose per body weight per day, the rat dose was 100 
times higher than the human dose. Again, this dose 
did not cause mucosal ulceration in a rat model.
The present study has several limitations. 
Confirmation of case status depended upon findings 
based on information in patients’ medical documents. 
This condition, particularly in milder forms, is often 
managed by dentists, who record their findings in 
dental, not medical, formats. Consequently, this 
would result in an underestimation of the number 
of BRONJ cases and would therefore hamper an 
accurate calculation of the true incidence of cases.
A clinical staging system has been developed in 
order to more accurately categorize patients with 
BRONJ22. In the early stages, surgical debridement 
and coverage are expected to be successful16. 
Segmental osteotomies are recommended only 
in severe cases9. However, this controversial 
treatment has a high morbidity and affects the 
patients’ quality of  life13. In the present study, 
the management of patients on bisphosphonate 
with bony exposure was conservative, and healing 
occurred just in about 21% of the patients. The 
difficulty in treating BRONJ has highlighted the 
importance of prevention.
CONCLUSION
Most of the BRONJ patients receiving 
corticosteroids had a non-healing bony lesion 
at the end of the present study period. In this 
retrospective study, the majority of patients had 
exposed bone despite conservative therapy. The 
difficulty in treating BRONJ has highlighted the 
importance of prevention. Further studies are still 
needed to identify the triggering factors associated 
with BRONJ and also to establish guidelines for the 
effective treatment of this condition.
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